Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

US Blepharoplasty Market

ID: MRFR/HC/14652-HCR
128 Pages
Rahul Gotadki
Last Updated: April 06, 2026

US Blepharoplasty Market Research Report Information By Type (Upper Eyelid Blepharoplasty, Lower Eyelid Blepharoplasty, and Combination Eyelid Surgery), By Gender (Female and Male), By Service Provider (Hospitals, Clinics, and Ambulatory Surgical Centre) –Market Forecast Till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

US Blepharoplasty Market Infographic
Purchase Options
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
  2.   1.1 EXECUTIVE SUMMARY
  3.     1.1.1 Market Overview
  4.     1.1.2 Key Findings
  5.     1.1.3 Market Segmentation
  6.     1.1.4 Competitive Landscape
  7.     1.1.5 Challenges and Opportunities
  8.     1.1.6 Future Outlook
  9. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
  10.   2.1 MARKET INTRODUCTION
  11.     2.1.1 Definition
  12.     2.1.2 Scope of the study
  13.       2.1.2.1 Research Objective
  14.       2.1.2.2 Assumption
  15.       2.1.2.3 Limitations
  16.   2.2 RESEARCH METHODOLOGY
  17.     2.2.1 Overview
  18.     2.2.2 Data Mining
  19.     2.2.3 Secondary Research
  20.     2.2.4 Primary Research
  21.       2.2.4.1 Primary Interviews and Information Gathering Process
  22.       2.2.4.2 Breakdown of Primary Respondents
  23.     2.2.5 Forecasting Model
  24.     2.2.6 Market Size Estimation
  25.       2.2.6.1 Bottom-Up Approach
  26.       2.2.6.2 Top-Down Approach
  27.     2.2.7 Data Triangulation
  28.     2.2.8 Validation
  29. 3 SECTION III: QUALITATIVE ANALYSIS
  30.   3.1 MARKET DYNAMICS
  31.     3.1.1 Overview
  32.     3.1.2 Drivers
  33.     3.1.3 Restraints
  34.     3.1.4 Opportunities
  35.   3.2 MARKET FACTOR ANALYSIS
  36.     3.2.1 Value chain Analysis
  37.     3.2.2 Porter's Five Forces Analysis
  38.       3.2.2.1 Bargaining Power of Suppliers
  39.       3.2.2.2 Bargaining Power of Buyers
  40.       3.2.2.3 Threat of New Entrants
  41.       3.2.2.4 Threat of Substitutes
  42.       3.2.2.5 Intensity of Rivalry
  43.     3.2.3 COVID-19 Impact Analysis
  44.       3.2.3.1 Market Impact Analysis
  45.       3.2.3.2 Regional Impact
  46.       3.2.3.3 Opportunity and Threat Analysis
  47. 4 SECTION IV: QUANTITATIVE ANALYSIS
  48.   4.1 Healthcare, BY Procedure Type (USD Million)
  49.     4.1.1 Upper Blepharoplasty
  50.     4.1.2 Lower Blepharoplasty
  51.     4.1.3 Double Eyelid Surgery
  52.     4.1.4 Transconjunctival Blepharoplasty
  53.   4.2 Healthcare, BY Demographics (USD Million)
  54.     4.2.1 Age Group
  55.     4.2.2 Gender
  56.     4.2.3 Income Level
  57.     4.2.4 Ethnicity
  58.   4.3 Healthcare, BY Surgical Technique (USD Million)
  59.     4.3.1 Traditional Surgery
  60.     4.3.2 Laser Surgery
  61.     4.3.3 Endoscopic Surgery
  62.     4.3.4 Non-Surgical Options
  63.   4.4 Healthcare, BY Indication (USD Million)
  64.     4.4.1 Cosmetic Enhancement
  65.     4.4.2 Functional Impairment
  66.     4.4.3 Reconstructive Surgery
  67.   4.5 Healthcare, BY Patient Type (USD Million)
  68.     4.5.1 First-Time Patients
  69.     4.5.2 Repeat Patients
  70.     4.5.3 Referral Patients
  71. 5 SECTION V: COMPETITIVE ANALYSIS
  72.   5.1 Competitive Landscape
  73.     5.1.1 Overview
  74.     5.1.2 Competitive Analysis
  75.     5.1.3 Market share Analysis
  76.     5.1.4 Major Growth Strategy in the Healthcare
  77.     5.1.5 Competitive Benchmarking
  78.     5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
  79.     5.1.7 Key developments and growth strategies
  80.       5.1.7.1 New Product Launch/Service Deployment
  81.       5.1.7.2 Merger & Acquisitions
  82.       5.1.7.3 Joint Ventures
  83.     5.1.8 Major Players Financial Matrix
  84.       5.1.8.1 Sales and Operating Income
  85.       5.1.8.2 Major Players R&D Expenditure. 2023
  86.   5.2 Company Profiles
  87.     5.2.1 Allergan (US)
  88.       5.2.1.1 Financial Overview
  89.       5.2.1.2 Products Offered
  90.       5.2.1.3 Key Developments
  91.       5.2.1.4 SWOT Analysis
  92.       5.2.1.5 Key Strategies
  93.     5.2.2 Revance Therapeutics (US)
  94.       5.2.2.1 Financial Overview
  95.       5.2.2.2 Products Offered
  96.       5.2.2.3 Key Developments
  97.       5.2.2.4 SWOT Analysis
  98.       5.2.2.5 Key Strategies
  99.     5.2.3 Medytox (US)
  100.       5.2.3.1 Financial Overview
  101.       5.2.3.2 Products Offered
  102.       5.2.3.3 Key Developments
  103.       5.2.3.4 SWOT Analysis
  104.       5.2.3.5 Key Strategies
  105.     5.2.4 Hugel (US)
  106.       5.2.4.1 Financial Overview
  107.       5.2.4.2 Products Offered
  108.       5.2.4.3 Key Developments
  109.       5.2.4.4 SWOT Analysis
  110.       5.2.4.5 Key Strategies
  111.     5.2.5 Galderma (US)
  112.       5.2.5.1 Financial Overview
  113.       5.2.5.2 Products Offered
  114.       5.2.5.3 Key Developments
  115.       5.2.5.4 SWOT Analysis
  116.       5.2.5.5 Key Strategies
  117.     5.2.6 Sientra (US)
  118.       5.2.6.1 Financial Overview
  119.       5.2.6.2 Products Offered
  120.       5.2.6.3 Key Developments
  121.       5.2.6.4 SWOT Analysis
  122.       5.2.6.5 Key Strategies
  123.     5.2.7 AptarGroup (US)
  124.       5.2.7.1 Financial Overview
  125.       5.2.7.2 Products Offered
  126.       5.2.7.3 Key Developments
  127.       5.2.7.4 SWOT Analysis
  128.       5.2.7.5 Key Strategies
  129.     5.2.8 Medytox (US)
  130.       5.2.8.1 Financial Overview
  131.       5.2.8.2 Products Offered
  132.       5.2.8.3 Key Developments
  133.       5.2.8.4 SWOT Analysis
  134.       5.2.8.5 Key Strategies
  135.     5.2.9 Hugel (US)
  136.       5.2.9.1 Financial Overview
  137.       5.2.9.2 Products Offered
  138.       5.2.9.3 Key Developments
  139.       5.2.9.4 SWOT Analysis
  140.       5.2.9.5 Key Strategies
  141.   5.3 Appendix
  142.     5.3.1 References
  143.     5.3.2 Related Reports
  144. 6 LIST OF FIGURES
  145.   6.1 MARKET SYNOPSIS
  146.   6.2 US MARKET ANALYSIS BY PROCEDURE TYPE
  147.   6.3 US MARKET ANALYSIS BY DEMOGRAPHICS
  148.   6.4 US MARKET ANALYSIS BY SURGICAL TECHNIQUE
  149.   6.5 US MARKET ANALYSIS BY INDICATION
  150.   6.6 US MARKET ANALYSIS BY PATIENT TYPE
  151.   6.7 KEY BUYING CRITERIA OF HEALTHCARE
  152.   6.8 RESEARCH PROCESS OF MRFR
  153.   6.9 DRO ANALYSIS OF HEALTHCARE
  154.   6.10 DRIVERS IMPACT ANALYSIS: HEALTHCARE
  155.   6.11 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
  156.   6.12 SUPPLY / VALUE CHAIN: HEALTHCARE
  157.   6.13 HEALTHCARE, BY PROCEDURE TYPE, 2024 (% SHARE)
  158.   6.14 HEALTHCARE, BY PROCEDURE TYPE, 2024 TO 2035 (USD Million)
  159.   6.15 HEALTHCARE, BY DEMOGRAPHICS, 2024 (% SHARE)
  160.   6.16 HEALTHCARE, BY DEMOGRAPHICS, 2024 TO 2035 (USD Million)
  161.   6.17 HEALTHCARE, BY SURGICAL TECHNIQUE, 2024 (% SHARE)
  162.   6.18 HEALTHCARE, BY SURGICAL TECHNIQUE, 2024 TO 2035 (USD Million)
  163.   6.19 HEALTHCARE, BY INDICATION, 2024 (% SHARE)
  164.   6.20 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Million)
  165.   6.21 HEALTHCARE, BY PATIENT TYPE, 2024 (% SHARE)
  166.   6.22 HEALTHCARE, BY PATIENT TYPE, 2024 TO 2035 (USD Million)
  167.   6.23 BENCHMARKING OF MAJOR COMPETITORS
  168. 7 LIST OF TABLES
  169.   7.1 LIST OF ASSUMPTIONS
  170.     7.1.1
  171.   7.2 US MARKET SIZE ESTIMATES; FORECAST
  172.     7.2.1 BY PROCEDURE TYPE, 2026-2035 (USD Million)
  173.     7.2.2 BY DEMOGRAPHICS, 2026-2035 (USD Million)
  174.     7.2.3 BY SURGICAL TECHNIQUE, 2026-2035 (USD Million)
  175.     7.2.4 BY INDICATION, 2026-2035 (USD Million)
  176.     7.2.5 BY PATIENT TYPE, 2026-2035 (USD Million)
  177.   7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  178.     7.3.1
  179.   7.4 ACQUISITION/PARTNERSHIP
  180.     7.4.1

US Healthcare Market Segmentation

Healthcare By Procedure Type (USD Million, 2026-2035)

  • Upper Blepharoplasty
  • Lower Blepharoplasty
  • Double Eyelid Surgery
  • Transconjunctival Blepharoplasty

Healthcare By Demographics (USD Million, 2026-2035)

  • Age Group
  • Gender
  • Income Level
  • Ethnicity

Healthcare By Surgical Technique (USD Million, 2026-2035)

  • Traditional Surgery
  • Laser Surgery
  • Endoscopic Surgery
  • Non-Surgical Options

Healthcare By Indication (USD Million, 2026-2035)

  • Cosmetic Enhancement
  • Functional Impairment
  • Reconstructive Surgery

Healthcare By Patient Type (USD Million, 2026-2035)

  • First-Time Patients
  • Repeat Patients
  • Referral Patients

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions